Your browser doesn't support javascript.
loading
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya, Takashi; Ishikawa, Nobuhisa; Kozuki, Toshiyuki; Kuyama, Shoichi; Inoue, Koji; Yokoyama, Toshihide; Kanaji, Nobuhiro; Yasugi, Masayuki; Shibayama, Takuo; Aoe, Keisuke; Ochi, Nobuaki; Fujitaka, Kazunori; Kodani, Masahiro; Ueda, Yutaka; Watanabe, Kazuhiko; Bessho, Akihiro; Sugimoto, Keisuke; Oze, Isao; Hotta, Katsuyuki; Kiura, Katsuyuki.
Affiliation
  • Ninomiya T; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Electronic address: ninomiya.takashi.se@mail.hosp.go.jp.
  • Ishikawa N; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Kozuki T; Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan.
  • Kuyama S; Department of Respiratory Medicine, National Hospital Organization, Iwakuni Clinical Center, Iwakuni, Japan.
  • Inoue K; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Yokoyama T; Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
  • Kanaji N; Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Yasugi M; Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan.
  • Shibayama T; Department of Respiratory Medicine, National Hospital Organization, Okayama Medical Center, Okayama, Japan.
  • Aoe K; Department of Medical Oncology, National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Japan.
  • Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
  • Fujitaka K; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kodani M; Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Japan.
  • Ueda Y; Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Watanabe K; Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan.
  • Bessho A; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
  • Sugimoto K; Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan.
  • Oze I; Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Hotta K; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Kiura K; Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan.
Lung Cancer ; 184: 107349, 2023 10.
Article in En | MEDLINE | ID: mdl-37651927
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Lung Cancer Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Lung Cancer Year: 2023 Document type: Article